Sorrento Therapeutics Inc (SRNE)

[DC Express]

GREAT NEWS FOR SRNE ANTIBODY TREATMENT - FDA just announced it is stopping the use of blood plasma from recovered patients as a source of much needed antibodies according to a report on CNN. This leaves the door open for SRNE new STI-1499 (COVI-GUARD) to be the source for hospitalized COVID-19 patients who need antibodies in the treatment and prevention of Covid-19 corona virus.

The SRNE initial trial is expected to be followed by pivotal trials with a goal of receiving an EUA (Emergency Use Authorization) as early as the end of this year.

Animal model data (Syrian Golden Hamsters infected with SARS-CoV-2) confirm the neutralizing profile and high potency of this antibody. The expected effective dose in humans is to be at least 5 times lower than current known antibodies being assessed in other active trials.

Additional in-vitro experiments demonstrated the complete virus neutralizing property of STI-1499 against the highly contagious D614G SARS-CoV-2 variant.

Sorrento has initiated cGMP manufacturing to produce 50,000 doses, expected to be available by the end of this year, in anticipation of a potential EUA.